What changed
$MDLZ — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $10.1B | EPS $0.67 vs $0.61 🟢 | Margin 11.4%
💡 Consensus models extrapolated muted top-line growth and margin pressure from commodity inflation. The 10% EPS beat, driven by better-than-expected gross margins and market share gains, implies that MDLZ is navigating cost headwinds more effectively than the market assumed.
📉 Reward/risk: 2.53:1
🏢 Business Quality: 8/10
📊 Valuation: fair — FCF yield 3.8% based on $3B 2026 guidance, slightly below the 4–4.5% typical for large-cap staples, indicating the stock is not cheap.
🔮 Catalyst: Post-earnings revision cycle: multiple sell-side analyst upgrades and price-target increases within 2–4 weeks, followed by management presentation at a consumer conference in April.
💰 Entry: $60.12, stop $57.0, target $68.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/MDLZ0620